

# 14°

## CONGRESSO NAZIONALE SINut

**SINut**  
Società Italiana di Nutraceutica

12-14 settembre 2024

Bologna



# SUPPLEMENTI DIETETICI NELLA GESTIONE DEL FOOD CRAVING E DEL SENSO DI SAZIETÀ

**Federica Fogacci**


Università di Bologna

***Il sottoscritto Federica Fogacci***


*ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 17 del Reg. Applicativo dell'Accordo Stato-Regione del 5 novembre 2009,*

dichiara

*che negli ultimi due anni NON ha avuto rapporti diretti di finanziamento con soggetti portatori di interessi commerciali in campo sanitario*



- Food cravings may be defined as **intense desires or urges** for a **particular type of food**
- Food craving may include intense and intrusive thoughts and multi-sensory imagery of a food; strong urges to seek and consume a food, perception of poor self-control with the food, and anticipation of positive and/or negative reinforcement if one eats the food
- State food cravings are regularly experienced by individuals with and without eating disorders



## Decision making tree to select a measure of food craving

A key limitation of self-report questionnaires is that they are subject to social desirability bias and demand characteristics. Also, the validity of these questionnaires may be limited because respondents may have different interpretation of items and response options. A third potential problem, relevant to measures assessing past experience of craving, are deficits in retrospective recall

- People **typically** report **craving highly processed, palatable foods** that contain high levels of refined carbohydrates, sugar, and/or fat
- Higher levels of craving intensity are associated with **more consumption of snacks** and this relationship is moderated by trait craving, with higher trait cravers showing higher levels of snack consumption
- Frequent and intense food cravings may serve as an impediment to psychological and emotional wellness, personal nutrition, health, and/or physical appearance goals




14°

CONGRESSO NAZIONALE SINut

SINut  
Società Italiana di Nutraceutica

12-14 settembre 2024

Bologna




Once Pandora's  
box is open,  
there is no going  
back!



A detailed historical illustration of a battle scene. In the center, a man in a yellow turban and brown tunic sits in a chariot, holding a spear. He is surrounded by soldiers on horseback, many of whom are also holding spears. The scene is filled with the chaos of battle, including fallen soldiers, broken weapons, and a large plume of smoke in the background. The overall style is reminiscent of a historical painting or a detailed woodcut.

# Nutraceuticals for Food Craving: a Story of Defeats



## A placebo controlled randomized clinical trial of *Crocus sativus* L. (saffron) on depression and food craving among overweight women with mild to moderate depression

Shahin Akhondzadeh PhD<sup>1</sup> | Seyed-Ali Mostafavi PhD<sup>1</sup> | Seyed Ali Keshavarz PhD<sup>2</sup> |  
 Mohammad Reza Mohammadi MD<sup>1</sup> | Saeed Hosseini PhD<sup>2</sup> |  
 Mohammad Reza Eshraghian PhD<sup>3</sup>




### Inclusion Criteria:

- Women
- BMI  $\geq 25$  Kg/m<sup>2</sup>
- Major depressive disorder

### Exclusion Criteria:

- Severe depression
- Other severe psychiatric disorders
- Treatment with medications which may affect the appetite and body weight



- Saffron capsule (30 mg/day *Crocus Sativus* L.) was **not effective** in reducing **food craving** or **body weight**, but as a safe over-the-counter supplement
- It may be helpful in patients with depression and BMI  $\geq 25$  Kg/m<sup>2</sup> for decreasing the symptoms of depression






## Body Weight Management in Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial



**Ashwagandha**  
(*Withania somnifera*)



- Ashwagandha root extract (300 mg;** containing 5% withanolides) resulted in a **marked reduction of** mean scores on the **Perceived Stress Scale** at both 4 and **8 weeks**, compared with baseline values and placebo group
- Food Craving** (FCQ-T assessed) also showed significantly **greater improvement** in the treatment group than the placebo group

## ORIGINAL ARTICLE


# Effect of a combined mulberry-sage dietary supplement on food craving and body weight: a pilot clinical trial

*Federica Fogacci<sup>1,2</sup>, Maddalena Veronesi<sup>1</sup>, Antonio Di Micoli<sup>1</sup>, Marilisa Bove<sup>1</sup>,  
Arrigo FG Cicero<sup>1,2</sup>*

<sup>1</sup>Hypertension and cardiovascular risk research group, Medical and Surgical Sciences Dept., Alma Mater Studiorum University of Bologna, Bologna, Italy; <sup>2</sup>Italian Society of Nutraceuticals (SINut), Bologna, Italy

# EFFECT OF MULBERRY AND SAGE ON FOOD CRAVING AND BODY WEIGHT


## A PILOT CLINICAL STUDY




This approach can support body weight loss by decreasing food craving in healthy overweight individuals



**IMPROVE GLUCOSE CONTROL**



**REDUCE SERUM MARKERS  
OF INFLAMMATION**



**REDUCE PLASMA LIPIDS**





## RESEARCH

## Open Access



## Mulberry leaf extract improves glycaemic response and insulaemic response to sucrose in healthy subjects: results of a randomized, double blind, placebo-controlled study

Pariyarth Sangeetha Thondre<sup>1</sup>, Helen Lightowler<sup>1</sup>, Lis Ahlstrom<sup>1</sup> and Andrew Gallagher<sup>2\*</sup> 




- The results showed a clear and significant effect of **250 mg white mulberry leaf extract** to **decrease** both **glucose** and **insulin** concentrations following a sucrose challenge in **normoglycemic individuals** ( $n=37$ )
- Both the peak blood glucose and blood insulin levels were lowered, as was the total postprandial glucose and insulin levels, as represented by iAUC




## Morus Alba leaf extract affects metabolic profiles, biomarkers inflammation and oxidative stress in patients with type 2 diabetes mellitus: A double-blind clinical trial

Mohsen Taghizadeh, Azam Mohammad Zadeh, Zatollah Asemi, Amir Hosein Farrokhnezhad, Mohammad Reza Memarzadeh, Zarin Banikazemi, Mohammad Shariat, Rana Shafabakhsh\*




- This study was carried out to determine the effect of **12-week** administration of **Morus Alba extract (300 mg twice a day)** on liver enzymes, biomarkers of inflammation and oxidative stress, insulin metabolism and lipid profiles in patients with **T2DM**
- Morus Alba extract had **beneficial effects** on **HDL-cholesterol, insulin** and **MDA** levels, but did not affect other metabolic profiles



## Impact of mulberry consumption on cardiometabolic risk factors: A systematic review and meta-analysis of randomized-controlled trials

Xibin Chen MD<sup>1</sup> | Mohammad Hassan Sohoulì PhD<sup>2</sup> | Mahsa Nateghi MSc<sup>3</sup> |  
Ebru Melekoglu PhD<sup>4</sup> | Somaye Fatahi PhD<sup>3</sup>



- Duration of intervention was ranged **from 4 to 48 weeks**
- The amount of administered mulberry ranged **between 6–1000 mg/day** among studies

- The present systematic review and meta-analysis of controlled clinical trials found that mulberry consumption significantly reduced **HbA1c**. Moreover, mulberry consumption beneficially reduced **total cholesterol, LDL-C, and TG**. Lastly, mulberry consumption favourably decreased **CRP** inflammatory marker as a predictor of CVD
- Subgroup analysis results showed that mulberry consumption **>300 mg/day** and **≤6 weeks** resulted in **greater reductions** in total cholesterol, TG, and LDL-C levels. Also, >300 mg daily intake of mulberry exhibited a favourable effect on serum HDL-C



**IMPROVE GLUCOSE CONTROL**




**REDUCE PLASMA  
LIPIDS**





Ali Abdollahi, Faeze Adelibahram, Nafiseh Ghassab-Abdollahi, Mostafa Araj-khodaei, Zahra Parsian and Mojgan Mirghafourvand\*

## The effect of *Salvia officinalis* on blood glycemic indexes and blood lipid profile in diabetic patients: a systematic review and meta-analysis



First author (year)	Country	Type of clinical trial	Sample size	Age of participants, years	Intervention (dosage + months of treatment)	Comparison (dosage + months of treatment)	Duration of follow up
Behradmanesh et al. (2013)	Iran	RCT	<i>Salvia officinalis</i> group = 40 Placebo group = 40	40–60	<i>Salvia officinalis</i> tablets (150 mg extract) 3 times a day for 3 months	Placebo 3 times a day	3 months
Kianbakht et al. (2013)	Iran	RCT	<i>Salvia officinalis</i> group = 44 Placebo group = 42	40–60	<i>Salvia officinalis</i> leaf extract (one 500 mg capsules) 3 times a day for 3 months	Placebo 3 times a day	3 months
Kianbakht et al. (2016)	Iran	RCT	Group:105 <i>Salvia officinalis</i> group = 52 Placebo group = 53	40–60	<i>Salvia officinalis</i> capsules(contained 500 mg of the extract powder) every 8 h (3 times a day) for 2 months	Placebo capsule every 8 h for 2 months	2 months



Ali Abdollahi, Faeze Adelibahram, Nafiseh Ghassab-Abdollahi, Mostafa Araj-khodaei, Zahra Parsian and Mojgan Mirghafourvand\*

## The effect of *Salvia officinalis* on blood glycemic indexes and blood lipid profile in diabetic patients: a systematic review and meta-analysis


The results of meta-analysis showed that *S. officinalis* has **significant effect** on :

- **FBS** (mg/dL) (n=3 studies; MD: -31.15; 95% CI: -37.56 to -24.73; p<0.00001)
- **HbA1c** (%) (n=2 studies; MD: -0.94; 95% CI: -1.25 to -0.63; p<0.00001)
- **Total Cholesterol** (mg/dL) (n=3 studies; MD: -43.64; 95% CI: -83.26 to -4.02; p=0.03)
- **Triglycerides** (mg/dL) (n=3 studies; MD: -39.78; 95% CI: -85.69 to 6.12; p=0.09)
- **LDL-C** (mg/dL) (n=3 studies; MD: -19.23; 95% CI: -35.81 to -2.65; p=0.02)
- **HDL-C** (mg/dL) (n=3 studies; MD: 6.15; 95% CI: -1.73 to 14.03; p=0.13)
- **2-HPPG** (mg/dL) (n=2 studies; MD: -49.24; 95% CI: -62.39 to -36.08; p<0.00001)



## Antihyperlipidemic Effects of *Salvia officinalis* L. Leaf Extract in Patients with Hyperlipidemia: A Randomized Double-Blind Placebo-Controlled Clinical Trial

S. Kianbakht,<sup>1\*</sup> B. Abasi,<sup>2</sup> M. Perham<sup>3</sup> and F. Hashem Dabaghian<sup>4</sup>



- **Total cholesterol, TG, LDL-C and VLDL-C** levels **decreased**, whereas **HDL-C** levels **increased** in the sage group after **4 months** compared to the baseline and compared to placebo
- No adverse effects were reported by patients

# TAKE HOME MESSAGES

**1**

Food cravings consists in an intense desires or urges for a particular type of food

**2**

Some botanicals can ameliorate food craving and potentially decrease the risk for the long-term metabolic consequences

**3**

Studies involving large numbers of individuals will be necessary to obtain further evidence on the topic

**THANKS FOR YOUR ATTENTION**

*... any question? E-mail me!*



*[federicafogacci@gmail.com](mailto:federicafogacci@gmail.com)*